Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...
We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...
A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centred on text messages she exchanged with the head of vaccine maker Pfizer during negotiations for Covid jabs, her lawyer ...
All vaccines that are authorised by regulatory authorities come with important safety information that should be carefully ...
Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for ...
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...